sel120
Small moleculeexperimental
Clinical trial activity
7 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
6
Phase 3
0
Phase 4
0
Earliest trial started Jul 15, 2019 (NCT04021368)
Timeline
Indications
Mechanism of action
CDK19 inhibitor
- Cell division protein kinase 8INHIBITOR
CDK8 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06987058 | Phase 2 | Dec 15, 2025 | Selvita S.A. |
| NCT06397313 | Phase 2 | Sep 19, 2024 | Selvita S.A. |
| NCT06243458 | Phase 2 | Sep 10, 2024 | GCP-Service International Ltd. & Co. KG, Medical University of Warsaw, Selvita S.A., University of Florence, University of Leipzig, University of Paris, University of Salamanca |
| NCT06268574 | Phase 2 | Jan 23, 2024 | Selvita S.A. |
| NCT06191263 | Phase 2 | Jan 5, 2024 | Selvita S.A. |
| NCT05052255 | Phase 1/Phase 2 (Phase 2) | Aug 13, 2021 | Selvita S.A. |
| NCT04021368 | Phase 1 | Jul 15, 2019 | ICON, Selvita S.A. |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Selvita S.A. | For profit | 7 | 6 | 2 | 2019 |
| GCP-Service International Ltd. & Co. KG | For profit | 1 | 1 | 1 | 2024 |
| ICON | For profit | 1 | 0 | 1 | 2019 |
| Medical University of Warsaw | Academic/Hospital | 1 | 0 | 1 | 2024 |
| University of Florence | Academic/Hospital | 1 | 0 | 1 | 2024 |
| University of Leipzig | Academic/Hospital | 1 | 0 | 1 | 2024 |
| University of Paris | Academic/Hospital | 1 | 0 | 1 | 2024 |
| University of Salamanca | Academic/Hospital | 1 | 0 | 1 | 2024 |
8 organizations
Page 1 / 1